Compare Coursera Inc (COUR) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Heron Therapeutics Inc — how do they compare? Coursera Inc trades at $5.25 (market cap $1.39B), while Heron Therapeutics Inc trades at $0.39 (market cap $68.01M). The key difference: Coursera Inc is far larger — about 20.4× Heron Therapeutics Inc's market cap, and Coursera Inc is more actively traded (9,728,980 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Heron Therapeutics Inc for 35 Days on average.
| COUR | HRTX | |
|---|---|---|
Market Cap | $1.39B | $68.01M |
Volume | 9,728,980 | 1,891,941 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $1.49 |
52-Week Low | $4.64 | $0.27 |
Typical Hold Time | 47 Days | 35 Days |
Enterprise Value | $648.49M | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.11, down 0.2% with bearish technical signals despite positive analyst sentiment. The company shows improving revenue growth from $524M in 2022 to $758M in 2025, though net losses persist at -$51M. Recent news highlights strong institutional interest with Deutsche Bank acquiring 1.7M shares and unusual options activity indicating bullish speculation. The stock faces technical resistance at $5 with RSI suggesting potential overbought conditions near-term.
While analyst consensus remains bullish with a $7.40 price target (44% upside), execution risks from ongoing losses and competitive pressures in edtech warrant caution. The company's Project Helix AI platform and 44% subscriber growth provide catalysts, but profitability challenges and integration costs from recent acquisitions present headwinds for investor returns.
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
